In Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D, a report from Insight Pharma Reports (formerly Advances Reports), author Allan B. Haberman, PhD, provides a strategic perspective on the field of drugs for diabetes and its complications, with an emphasis on novel and emerging drugs and therapeutic strategies.
For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D
Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.
*Report is available for single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.